[Application and Research Progress of Selinexor in Hematologic Tumors Other Than Multiple Myeloma --Review].

Exportin-1 (XPO1) is a major transporter for hundreds of proteins. Selinexor is the first generation XPO1 inhibitor. At present, selinexor has gained more attention in the application of multiple myeloma (MM).

[Research Progress of Transmembrane Protein Abnormality in Non-Hodgkin's Lymphoma --Review].

Transmembrane protein, also known as integral membrane protein, can be distributed in the lipid bilayer or across the entire membrane, and it plays an important role in cell signal transduction. It has been discovered that multiple transmembrane proteins are involved in the regulation of tumor signals. Recent studies have revealed that the abnormal expression of some transmembrane protein is closely related to the occurrence, development and prognosis of non-Hodgkin's lymphoma (NHL), including programmed cell death protein 1 (PD-1), TMEM30A, NOTCH1, TOLL-like receptor (TLR), sphingosine-1-phosphate receptor, TRAIL, etc.

[Molecular Characteristics and Clinical Significance of IGH Gene Rearrangement in B-Cell Lymphoma--Review].

B-cell lymphoma is the most common malignant lymphoma, and its incidence is increasing year by year. Some types are often indistinguishable from the reactive lesions through morphology combined with immunohistochemistry, so other auxiliary diagnostic methods are urgently needed. Since B-cell lymphoma is caused by malignant transformation of IGH rearranged B cells, the molecular characteristics of rearranged B cells can be used as an important reference for differentiating benign and malignant proliferations of lymphatic tissues.

[Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review].

T-cell prolymphocytic leukemia (T-PLL) is a rare but highly aggressive and malignant mature T-lymphoid tumor. The diagnosis of T-PLL mainly depend on genetic characteristics, clinical manifestations, cell morphology and immunophenotype. At present, clinical treatment is mainly aimed at improving the response rate and prolonging the remission period.

[Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia: Pathological Mechanism and Treatment Progress---Review].

Chronic lymphocytic leukemia (CLL) patients usually show immune dysfunction, which often leads to autoimmune hemocytopenia. Immune thrombocytopenia (ITP) is one of the common complications. The pathogenesis of CLL-related ITP is complex and has not been fully elucidated.